Targeted drug trial offers hope for lung Cancer's most devastating spread
NCT ID NCT04563871
Summary
This study tested whether the drug osimertinib could help control a serious complication where lung cancer spreads to the membranes surrounding the brain and spinal cord. It involved 73 adults in South Korea with a specific genetic mutation in their lung cancer who had already tried other targeted therapies. The main goal was to see if the daily pill could help patients live longer by controlling this difficult-to-treat spread of the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, South Korea
-
ChungBuk National University Hospital
Cheonju, South Korea
-
National Cancer Center
Goyang, South Korea
-
Samsung Medical Center
Seoul, 135-710, South Korea
-
Seoul National University Bundang Hospital
Seongnam, South Korea
-
Seoul National University Hospital
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.